v W

products.,type:text}, {identifier: anf-body-
41,inlineTextStyles:[{range: {length:258, start:0},textstyle: anf-ts-
I}, {range™: {length:258,start:0},textStyle: anf-ts-1}],layout:default-
body, role:body, text:In restricting access to Revlimid and Thalomid, Celgene
relied on a federal requirement that the distribution of those drugs be tightly
regulated because of their dangerous side effects under a program known as Risk
Evaluation and Mitigation System, or
REMS., type: text }, {components:[{caption:Elaine Kodish, who lives in Los
Angeles, said she pays $785 a month for Revlimid, a drug produced by Celgene that helps
treat her multiple myeloma. Emily Berl for The New York

Times, captionComponent: {text:Elaine Kodish, who lives in Los Angeles, said she
pays $785 a month for Revlimid, a drug produced by Celgene that helps treat her

multiple myeloma. Emily Berl for The New York

Times},identifier™:100000006098034 S5ba8b8041267d, imageIdentifier™: 32d2f6bc7b8b
dbJVabad5d6cab07a43, layout: fullbleed-

image, role:photo, type:scalable image}, {identifier: anf-caption-
4,inlineTextsStyles: [{range:{Llength:34,start:147},textStyle:photo-
credit}],layout:default-caption, role: caption, text:Elaine Kodish, who lives

in Los Angeles, said she pays $785 a month for Revlimid, a drug produced by Celgene
that helps treat her multiple myeloma. Emily Berl for The New York Times

,type™:text}],identifier: anf-container-3, layout: image-

container, role:container, type:container}, {identifier: anf-body-
42,inlineTextStyles:[{range:{length:111,start:0},textsStyle: anf-ts-
i}, {range™:{length:111,start:0},textStyle: anf-ts-1}],layout:default-
body, role:body, text:Congress expressly prohibited drug companies from using
these programs to block or delay generic drug

approval.,type:text}, {identifier: anf-body-
43,“inlineTextStyles:[{range:{length:88,start:0},textStyle: anf-ts-

i}, {range™:{length:88,start:0},textStyle: anf-ts-1}],layout:default—

body, role:body, text:Yet, according to three lawsuits filed by generic drug

companies, Celgene did just that.,type:text}, {identifier: anf-body-
44,“inlineTextStyles:[{range: {length:315, start:0},textsStyle: anf-ts-
i™}, {range™:{length:315,start:0},textStyle: anf-ts-1}],layout:default-

body, role:body, text:It began with a simple refusal to distribute samples of
their drugs, citing REMS and demanding that generic drug companies provide written
confirmation from the F.D.A. permitting Celgene to provide drug samples. In the case of
Mylan, one of the generic drug companies that sued Celgene, this process took 19

months., type: text}, {identifier: anf-body-
45,inlineTextStyles:[{range: {length:251, start:0},textstyle: anf-ts-
I}, {range™:{length:251,start:0},textStyle:_ anf-ts-1}],layout:default—

body, role: body, text:After the generic companies sent approval from the F.D.A.,
Celgene would request more information before agreeing to distribute the drug. But
according to court documents in the Mylan case, these requests were laborious,

irrelevant and time consuming.,type™:text}, {identifier: anf-body-
46,inlineTextStyles: [{range: {length:244,start:0},textsStyle: anf-ts-

i}, {range™:{length:244,start:0},textStyle:_anf-ts-1}],layout:default-
body, role:body, text:The voluminous requests from Celgene became a rinse-and-

repeat cycle for many of the generic drug companies, according to court documents. Two
companies, Lannett and Barr Laboratories, settled with Celgene. Mylande€™s suit will

soon head to trial.,type:text}, {identifier: anf-body-
47,“inlineTextStyles:[{range: {length:208, start:0},textsStyle: anf-ts-

i}, {range™:{length:208,start:0},textStyle: anf-ts-1}],layout:default-—
body, role: body, text: aeeThis is really concerning conduct and Celgene is by far

the worst offender,d4€ Michael Carrier, a professor at Rutgers Law School who studies
patent law, said of Celgenead€e™s tactics to delay generic

development., type: text}, {identifier: anf-heading4-
4,layout:heading4, role: heading4,text: Campaign attack ads over soaring drug
prices, type™:text}, {additions™: [{URL:https://poll.qu.edu/new-jersey/releas
detail ?ReleaseID=2563,range:{length:27,start:160},type:link}],identifier:
_anf-body-48, inlineTextStyles: [{range™: {length:295,start:0},textStyle:_ anf-
ts-1},{range™:{length:295,start:0},textStyle: anf-ts-1}],layout:default-
body, role:body, text:As the Senate race careens toward the final weeks, the
Menendez campaign has seen some troubling signs in recent polling. Despite maintaining
a six-point lead, a Quinnipiac poll in August found that 49 percent of New Jersey
voters believed that Mr. Menendez a€ewas involved in serious

wrongdoing.a4€, type:text}, {additions: [{URL:https://www.youtube.com/watch?v=XE
lizocN4sé&feature=youtu.be, range: {length:21,start:150},type™:Link}, {URL:htt

HOUSE_OVERSIGHT_028420
